Abstract
Childhood tuberculosis (TB) continues to be a neglected disease in areas where limited resources restrict the focus of national TB control programmes to only the most infectious sputum smear-positive cases. However, appreciation that children contribute a significant proportion to the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The World Health Organization (WHO) published guidelines on the management of paediatric TB in 2006 and child friendly drug formulations have been made available to deserving nations via the Global Drug Facility (GDF) since 2008. These advances also served to emphasize the considerable programmatic barriers that remain in resource- limited settings. This review provides an overview of current treatment practices, presenting the authors personal perspectives on issues related to the treatment of childhood TB, together with a brief synopsis of potential future treatment options.
Keywords: Pediatric tuberculosis, management, treatment, TB, infectious sputum, GDF, current treatment practices, childhood TB, future treatment options, children, bacterial pneumonia, HIV, respiratory disease, first-line antibiotics, endemic areas
Infectious Disorders - Drug Targets
Title: Management of Tuberculosis in Children and New Treatment Options
Volume: 11 Issue: 2
Author(s): B. J. Marais, H. S. Schaaf and P. R. Donald
Affiliation:
Keywords: Pediatric tuberculosis, management, treatment, TB, infectious sputum, GDF, current treatment practices, childhood TB, future treatment options, children, bacterial pneumonia, HIV, respiratory disease, first-line antibiotics, endemic areas
Abstract: Childhood tuberculosis (TB) continues to be a neglected disease in areas where limited resources restrict the focus of national TB control programmes to only the most infectious sputum smear-positive cases. However, appreciation that children contribute a significant proportion to the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The World Health Organization (WHO) published guidelines on the management of paediatric TB in 2006 and child friendly drug formulations have been made available to deserving nations via the Global Drug Facility (GDF) since 2008. These advances also served to emphasize the considerable programmatic barriers that remain in resource- limited settings. This review provides an overview of current treatment practices, presenting the authors personal perspectives on issues related to the treatment of childhood TB, together with a brief synopsis of potential future treatment options.
Export Options
About this article
Cite this article as:
J. Marais B., S. Schaaf H. and R. Donald P., Management of Tuberculosis in Children and New Treatment Options, Infectious Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152611795589645
DOI https://dx.doi.org/10.2174/187152611795589645 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Macrocyclic Proteasome Inhibitors
Current Medicinal Chemistry In-Silico Characterization of a Hypothetical Protein, Rv1288 of Mycobacterium tuberculosis Containing an Esterase Signature and an Uncommon LytE Domain
Current Computer-Aided Drug Design Marine Sponges: Potential Sources of New Antimicrobial Drugs
Current Pharmaceutical Biotechnology Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Facile Microwave-assisted Synthesis of Various C5-modified Pyrimidine Pyranonucleosides as Potential Cytotoxic Antitumor Agents
Current Microwave Chemistry Metabolism Evolution Based on Network Degrees of Orthologous Enzymes
Current Topics in Medicinal Chemistry Synthesis, Characterizations and Microbial Studies of Novel Mannich Products Using Multicomponent Reactions
Current Bioactive Compounds Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry Editorial (Thematic Issue: Nanotechnology for Drug Delivery: Part I)
Current Pharmaceutical Design A Review of the Biological Activities of Heterocyclic Compounds Comprising Oxadiazole Moieties
Current Topics in Medicinal Chemistry Αlpha-2 Adrenergic and Opioids Receptors Participation in Mice Gastroprotection of Abelmoschus esculentus Lectin
Current Pharmaceutical Design Synthesis and Antibacterial/Antitubercular/Antioxidant Activities of Compounds Containing Fluoroquinolone Ring Linked to a 4-thiazolidinone Moiety
Letters in Drug Design & Discovery Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design One-Pot Synthesis of 5-Unsubstituted-6-Aroyl[1,2,4]triazolo[1,5-a]pyrimidine Utilizing Biginelli-Like Multicomponent Reaction of Enaminones with 3-Amino-1,2,4- triazole as the Urea Component
Current Organic Synthesis Benzoylthioureas: Design, Synthesis and Antimycobacterial Evaluation
Medicinal Chemistry Structural and Binding Properties of the Active Cell Wall Hydrolase RipA from <i>M. tuberculosis</i>, a Promising Biosensing Molecule for Early Warning Bacterial Detection
Current Medicinal Chemistry Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4
Current Pharmaceutical Design Synthesis of 2-Hydroxynaphthyl Pyrazolines Containing Isoniazid Moiety: A Potential Antitubercular Agent
Letters in Organic Chemistry Development and Characterization of Spray Dried Microparticles for Pulmonary Delivery of Antifungal Drug
Current Drug Delivery